Mithra Pharmaceuticals

[Kolibri007]

De CEO maakt vandaag een goede indruk en brengt duidelijk een andere wind. Een goede communicatie helpt in het verhaal naar investeerders en aandeelhouders. Het product was al goed, nu de rest op de rails krijgen maar mijn vertrouwen is na vandaag wel gestegen voor de lange termijn.

[Xem]

De CEO maakt vandaag een goede indruk en brengt duidelijk een andere wind. Een goede communicatie helpt in het verhaal naar investeerders en aandeelhouders. Het product was al goed, nu de rest op de rails krijgen maar mijn vertrouwen is na vandaag wel gestegen voor de lange termijn.

Vlotte pen en prachtige opsomming van potentiële cliffhangers … uit kijken waar we over exact één jaar staan. Koersdoel van 22€ ING , ze zijn daarvoor nog goed wakker.

[Hoebeet]

..."Hun boodschap was: ‘Los de bestuurlijke problemen bij Mithra op en we zullen investeren"...

Ik zou me zomaar kunnen voorstellen dat dat stelletje graaiende grabbelaars er zélf de oorzaak van was dat er
niet op een normale manier geld kon worden opgehaald.

Nu maar eens afwachten of dat onder het nieuwe bewind wél gaat lukken. Tegen acceptabele prijzen en voor-
waarden dan. Eventuele terugkeer naar 'n miljard beurswaarde is uiteraard leuk; maar dat moet niét via twee
miljard stukkies gaan

[Brahim_av]

Om even te herinneren aan Mithra's verlies en cashpositie verleden tot nu.
De kaspositie eind 2019 was €50 miljoen.
De kaspositie eind 2020 was €139 Miljoen. (netto verlies € 92 Miljoen in 2020)
De kaspositie eind 2021 was €33 Miljoen. (netto verlies €117 Miljoen in 2021)

De kaspositie eind 2022 was €28.3 Miljoen (netto verlies €60 Miljoen in 2022)

De LA met G.R. bracht 50Miljoen euro op in February 2023.
Bij ondertekenen van de BTS met G.R. in December was al € 5 miljoen uitbetaald

De kaspositie eind february 2023 was 67.5 miljoen euro.
De kaspositie eind april 2023 was ongeveer 26 miljoen euro.

Geschatte Cashburn in 2023
R&D = ______________________________ €60M
Cost of sales = ________________________€20M
general & admin expenses = ____________ €15M
Depreciation = _______________________ €10M
Betalingen aan ex-UTERON shareholders = _€15M
Other expenses= ______________________ €10M

[Hoebeet]

...En die 2,20? Mócht de gelegenheid zich nog voordoen, dan gún H&W hun 8% op 2,38 en pak er zélf 10 op 2,62

Goed plan. Vóórbeurs 'n order inleggen was minder

Die flinke cashdip van Februari naar nu viel mij ook op. Zou er dan toch iets met PCAS zijn geregeld?

[Hoebeet]

Niets daarover op de PCAS-site.

[Brahim_av]

Ik zie alleen nog verdere verwatering van de koers nu Tranche C in zicht komt en de
rente op de leningen omhoog gaat.
De cashpositie eind april van €26 M is maar heel magertjes, daar kan je geen 8 maand mee overbruggen.
Die € 55 Miljoen upfront van G.R. is er wel snel doorgejast precies.
En van Estelle moeten we dit jaar ook niet veel verwachten precies, dat had ik wel eerder opgemerkt.
Als Mithra verder wacht met een Donesta deal voor de VS uit te stellen tot December dit jaar
zie ik de koers zwaar onder druk komen te staan < €2?

[Brotherhood]

Ik had al een tijdje de indruk dat de moderator van beursig in slaap gedommeld was , nu ben ik er zeker van ....

[opportunist]

Ik had al een tijdje de indruk dat de moderator van beursig in slaap gedommeld was , nu ben ik er zeker van ....

Ik dacht dat dat een illustratie was van de de bijwerkingen van Estelle en Donesta in deze FASE.

[Xem]

https://www.marketscreener.com/amp/quot ... -43958939/

Mithra's General Meeting Of Shareholders Approves the Renewal of its Board of Directors
Today at 10:00 am
MITHRA PHARMACEUTICALS S.A.
2.350 EUR -2.89%
Liege - Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces that at its Annual General Meeting, held today the appointment/renewal of the following Directors for a two-year mandate was approved.

The Board of Directors is now made up of 6 members with varied backgrounds spanning both the financial and pharmaceutical sectors, bringing extensive expertise to Mithra covering all aspects of pharmaceutical development.

The Board will include four new Directors, including: Ribono SRL, Mr. Sidney Bens (Independent Director)

Sidney is a seasoned financial executive, with over 35 years' experience. He spent most of his career at Atenor, an international real estate development company listed on Euronext, where he served as Chief Financial Officer. Prior to this he worked in banking, as Senior Corporate Banker at Paribas Bank Belgium (now Belfius) and in Retail and SMC banking at BBL (now ING). Sidney holds a Masters degree in Finance, Accounting and Trade from Lucien Cooremans Institute, Belgium and a Postgraduate in Finance from KU Leuven, Belgium.

Mrs. Igne Beernaert (Independent Director)

Igne is an experienced financial services professional, specializing in audit, corporate finance, internal controls, tax, management and M&A. She is the founder of Bedrijfsrevisor Beernaert, a financial advisory firm that provides audit, M&A and strategic financial consulting for growing companies, where she served as company auditor for the last 27 years. Prior to this, she founded bb3 Revisoren, another financial advisory firm. Igne holds a Masters degree in Applied Economics from KU Leuven, Belgium and a postgraduate degree in liability and insurance law from the University of Antwerp.

Life Science Strategy Consulting SRL, Mr. Christian Homsy (Independent Director)

Christian is a leading life sciences executive with over 30 years' industry experience. Most recently he founded and served as interim Chief Executive Officer and Board Member of biotechnology company Capstan Therapeutics. He was also founder, Chief Executive Officer and Board Member of Celyad SA for 15 years. He spent a large part of his career at Guidant Corporation (part of Boston Scientific and Abbott Labs) in a number of senior roles. Christian gained his Medical Doctorate at the University of Louvain, Belgium and his MBA at IMD Business School, Lausanne, Switzerland.

Gaudeto SRL, Mr. Jacques Galloy (Independent Director)

Jacques has over 25 years of business leadership experience including private and public equity capital markets, focusing on digital imaging, medical technology, digital media and digital transition. He is currently the founder and managing partner of Guadeto SPRL, an investment consultancy firm advising small to mid-size media, health technology and digital transition companies. He is a current investor in 7 companies, entrepreneur in 5 businesses and charities, and has over 10 board mandates. He also has 12 years' experience as Board member and CFO of EVS Broadcast Equipment SA, a worldwide leader in TV Technology niches and a top 30 Belgian listed company. Jacques holds a Masters in Commercial Engineering from Ulg-HEC Liege, Belgium.

David Horn Solomon, CEO, commented: ' It is fantastic to welcome such established and experienced professionals to the Mithra Board of Directors. Their collective knowledge spanning both the financial and life sciences sectors will be invaluable to the Company as we continue the commercialization of our lead product, Estelle and develop our exciting and innovative pipeline of products to address key unmet need.

The General Meeting also renewed the mandates of: Alius Modi SRL, Ms. Valerie Gordenne (Non-Executive Director)

Valerie has over 20 years of experience in pharmaceutical Research & Development with extensive leadership experience in full drug development across a range of therapeutic areas in particular in women's health (CSO Mithra, CEO Novalon, General Manager Odyssea). Through the management of various functions and activities, she has developed a deep operational and strategic knowledge in drug development. She is currently Chief Scientific Officer at Auxin Surgery, CEO of the start-up Odix and an advisor in regulatory affairs. She has a Masters in Pharmaceutical Science, University Of Liege, Belgium and a Masters in Industrial Pharmacy from Inter-University, Belgium.

Eva Consulting SRL, Prof. Jean-Michel Foidart (Executive Director)

Co-founder of Mithra, Jean-Michel is a trained doctor specializing in Obstetrics and Gynecology and is the author of more than 1300 publications on women's health and experimental oncology. He is a member of many national and international scientific committees and is currently a Board member of the International Society of Gynecological Endocrinology. Jean-Michiel holds the Francqui Chair, Doctor Honoris Causa of the Pierre and Marie Curie University of Paris and the Paul Sabatier University of Toulouse. Professor Extraordinary, Honorary of the ULg and Perpetual Secretary of the Royal Academy of Medicine of Belgium. Professor Foidart graduated in Gynecology from the University of Liege and also obtained a PhD in cell biology and biochemistry, before directing its Department of Gynecology-Obstetrics.

Contact:

Tel: +32 (0)4 349 28 22

Email: [email protected]

(C) 2023 Electronic News Publishing, source ENP Newswire